Although there is extensive evidence of declines in the American Kestrel (Falco sparverius) population across North America, the cause of such declines remains a mystery. One hypothesized driver of decline is anticoagulant rodenticide (AR) exposure, which could potentially cause mortality or reduced fitness. We investigated AR exposure in wild American Kestrels in Utah, USA. We collected and tested for AR residues in liver samples (n = 8) from kestrels opportunistically encountered dead and in blood samples (n = 71) from live wild kestrels, both nestlings and adults. We found high detection rates in both tissues. Adult kestrels were more likely to exhibit exposure than juveniles sampled in nests. Three-quarters (six of eight) of tested liver samples from adult kestrels exhibited evidence of AR exposure. Additionally, liver samples (n = 19) opportunistically collected from seven species of raptors within our study area had detectable levels of AR residues, with seven of eight raptor species evidencing exposure; across all raptors, five ARs were detected in liver samples, with brodifacoum the most prevalent, being found in over half (14 of 27) of samples. Over half (7 of 12) of the blood samples from adult kestrels had detectible levels of ARs, while only one of 59 juvenile nest samples tested positive. The difference in exposure rates between adults and juveniles could indicate differential exposure pathways by age class. Based on these findings, we recommend that ARs be further investigated as a potential cause of kestrel declines. Future research could focus on expanding sampling to provide sufficient sample sizes to test for potential nonlethal effects of AR exposure (e.g., fecundity, nesting success), identifying potential exposure pathways, and developing methods for passive sampling of ARs in excreta.

Author(s): Quinn, Niamh; Swift, Catherine E. | Abstract: Anticoagulant rodenticides have been detected in many species of wildlife worldwide; yet the origins, exposure pathways, and effects of this exposure are not well understood. Furthermore, to accurately characterize the risks from rodenticide use, information is needed on what proportion of populations are being exposed, what proportion of the exposed individuals are affected, and in what ways. The relationship between anticoagulant rodenticide concentrations found in wildlife and the rate of mortality or illness is the subject of much current research. Residue levels observed in liver and whole body analyses vary, and overlap extensively among apparently healthy asymptomatic individuals and sublethal and lethal cases. Results from laboratory studies also show there can be wide variability in lethal and sublethal effects among and within taxonomic groups. Correlating the sublethal and reproductive effects observed in laboratory studies with realistic exposure scenarios and effects in the wild is needed to improve risk assessments. For species with limited numbers/declining populations, a critical question is whether the rodenticide exposure documented in individual animals inhibit population growth or contribute to population declines by lowering survival and reproductive success. This information is essential to the regulatory agencies that must weigh the risks and benefits of rodenticide uses and identify restrictions that are effective in reducing risks to wildlife. A primary objective of this symposium was to facilitate communication between regulators and researchers. Current research on many of these topics was presented, and was followed by discussions on how to improve our understanding of what factors lead to wildlife exposure and improve our ability to assess the effects of exposure on individuals and populations. A collaborative approach will be developed to design studies that provide regulatory and wildlife management agencies with additional science on which to base their decisions.

The anticoagulant rodenticides brodifacoum, chlorophacinone, and diphacinone have been proposed for broadcast application in some forested areas in Hawai'i to protect rare and endangered native bird species from introduced mice and rats. Groundwater resources in Hawai'i are prone to contamination due to the intrinsic aquifer vulnerability to leaching from the land surface. Because of the hydrogeologic complexity, Hawai'i uses a Tier-I leaching assessment tool, CLERS, to make registration decisions for new or existing chemicals. The CLERS tool uses soil and pesticide properties as well as water recharge through the soil profile in a GIS framework to estimate mass attenuation of the chemicals at a given depth and compares against this attenuation factor against those of a known leacher and a non-leacher. Disturbed soil samples were collected across the state of Hawai'i, including the islands of Hawai'i, Kaho'olawe, Kaua'i, Lana'i, Maui, Moloka'i, and O'ahu, with two sampling locations per island, except for Kaua'i which had three. As only limited information on chemical properties of these anticoagulants in soils is available, laboratory experiments were performed to determine the sorption capacity (Kd) and the degradation rate (T1/2) of brodifacoum, chlorophacinone, and diphacinone to construct a proper chemical database. Depending on the soil type, T1/2 values ranged between 37 and 248days for diphacinone, between 39 and 1000days for chlorophacinone, and between 72 and 462days for brodifacoum. These data were used in the CLERS tool to estimate leaching risks for these chemicals primarily in forested areas of the state where the chemicals are likely to be applied. The results from the CLERS tool indicate low risks of leaching of these three compounds into aquifers in five out of six major Hawaiian Islands. Diphacinone showed medium risk of leaching in a few remote areas in Maui.

In the early 1990s, a coalition of federal and state agencies, NGOs, and private landowners in Hawaii agreed to pursue a Special Local Needs pesticide registration (24(c) FIFRA) for the aerial broadcast of a 0.005% diphacinone rodenticide for the control of rodents in native ecosystems. While there was recognition of the important role introduced rodents play in the decline and extinction of native species, there were concerns expressed about the potential non-target impacts of this technique. Over the next 10 years, numerous studies were undertaken to address specific non-target issues. This research, along with other published and unpublished research on diphacinone and its human pharmaceutical counterpart, Dipaxin, was compiled and analyzed in 4 hazard assessments (human dietary and drinking water consumption, aquatic and terrestrial non-target species) that comprise the foundation of Hawaii's registration application. Hazards to humans and other non-target terrestrial organisms were evaluated in terms of dietary intake of contaminated food or water required before lethal or sublethal effects might be anticipated. Hazard to aquatic organisms was assessed according to traditional risk quotient methods employed by the U.S. Environmental Protection Agency. These assessments indicate the greatest human health hazard is to pregnant women drinking untreated stream water; however, even this risk is low. With a few exceptions, such as the Hawaiian crow, the ecological assessments indicate the acute risks to terrestrial or aquatic non-target species are minimal, even under the most conservative risk scenarios. However, there could be detectable physiological effects in birds exposed at sublethal levels. We believe that under proper supervision, this technique can be safely used in Hawaii, and elsewhere, to protect native species from the impacts of introduced rodents.